CRDL

Cardiol Therapeutics Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website cardiolrx.com
Employees(FY) -
ISIN CA14161Y2006

Performance

-5.88%

-22.42%

-43.11%

-38.46%

+51.8%

YTD

+45.44%

Profile

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.

Advanced Technical Analysis

Technical Analysis of CRDL 2024-12-20

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 3 and the Technical Score at 21, both indicating weak performance. The Oscillators Score of 40 suggests a neutral stance, but overall, the combined scores point to a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CRDL

Stock Rank

Recent News & Updates

2024-12-18 19:30
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis(Yahoo Finance)
2024-12-18 19:30
PRISM MarketView Features QandA with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis(Globenewswire)
2024-11-17 22:37
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024(Newsfilecorp)
2024-11-12 19:00
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index(Globenewswire)
2024-10-21 14:30
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis(Newsfilecorp)
2024-10-10 20:39
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option(Newsfilecorp)
2024-10-09 21:09
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares(Newsfilecorp)
2024-10-08 19:58
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares(Newsfilecorp)
2024-10-08 04:01
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares(Newsfilecorp)
2024-09-23 19:27
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis(Newsfilecorp)
2024-09-09 19:27
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024(Newsfilecorp)
2024-08-12 10:53
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q2 2024(Investorplace)
2024-06-27 00:29
Cardiol Therapeutics Reports Results of 2024 Annual General and Special Meeting of Shareholders(Newsfilecorp)
2024-06-24 19:27
Cardiol Therapeutics to Webcast Virtual Annual General and Special Meeting of Shareholders on June 26th at 4:30 p.m. EDT(Newsfilecorp)
2024-06-16 19:00
Hope on the Horizon: Results from MAvERIC-Pilot Show Heartfelt Progress for Patients(Newsdirect)
2024-06-12 19:58
Cardiol Therapeutics Announces Positive Topline Data from its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis(Newsfilecorp)
2024-06-10 18:00
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development(Newsdirect)
2024-06-02 19:00
Sector Spotlight: Orphan Drug Developers With Significant Upside(Newsdirect)
2024-05-27 19:00
Analysts' Consensus Reaffirms Significant Upside Potential for Cardiol Therapeutics(Newsdirect)
2024-05-14 10:53
CRDL Stock Earnings: Cardiol Therapeutics Meets EPS for Q1 2024(Investorplace)
2024-05-13 19:27
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024(Newsfilecorp)
2024-05-13 00:19
Canadian Investment Regulatory Organization Trading Halt - CRDL.WT.A(Yahoo Finance)
2024-04-01 21:53
CRDL Stock Earnings: Cardiol Therapeutics Beats EPS for Q4 2023(Investorplace)
2024-04-01 18:00
Cardiol Therapeutics Announces Year-End 2023 Update on Operations(Newsfilecorp)
2024-03-04 07:28
11 Best Small Cap Pharma Stocks to Invest In(Insidermonkey)
2024-02-20 18:27
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis(Newsfilecorp)
2024-02-14 18:27
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis(Newsfilecorp)
2024-01-23 18:27
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market(Newsfilecorp)
2024-01-08 18:27
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis(Newsfilecorp)
2023-12-04 18:27
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot(Newsfilecorp)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.